ContraVir gains rights to Chimerix's Phase I antiviral
Chimerix Inc. licensed ContraVir Pharmaceuticals Inc. exclusive rights to develop and commercialize CMX157, which is an analog of Gilead’s marketed antiviral Viread (tenofovir).
- Includes Equity
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.